for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Circassia Pharmaceuticals PLC

CIRCI.L

Latest Trade

16.92GBp

Change

0.05(+0.27%)

Volume

55,302

Today's Range

16.80

 - 

16.92

52 Week Range

13.25

 - 

67.60

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Latest Developments

Circassia Pharma 40% Revenue Growth To £27.9 Million In H1

Sept 26 (Reuters) - Circassia Pharmaceuticals PLC <CIRCI.L>::CIRCASSIA PHARMACEUTICALS PLC - 40% REVENUE GROWTH TO £27.9 MILLION IN H1 2019.CIRCASSIA PHARMACEUTICALS PLC - FULL YEAR 2019 REVENUE EXPECTATION £60 MILLION - £65 MILLION.CIRCASSIA PHARMACEUTICALS - FOCUS ON COST CONTROL TO ACHIEVE POSITIVE EBITDA ON ABOUT £75 MILLION NET ANNUAL SALES.CIRCASSIA PHARMACEUTICALS - HY UNDERLYING OPERATIONS LOSS BEFORE TAX 19.4 MILLION STG VERSUS LOSS OF 14.3 MILLION STG.

Invesco Discloses 21.44% Stake In Circassia Pharmaceuticals As Of Sept 16 Vs Prior Stake Of 22.78% - Filing

Sept 17 (Reuters) - Circassia Pharmaceuticals PLC <CIRCI.L>::INVESCO LTD DISCLOSES 21.44% STAKE IN CIRCASSIA PHARMACEUTICALS PLC AS OF SEPT 16 VERSUS PRIOR STAKE OF 22.78% - FILING.

Woodford Investment Management Discloses Less Than 5% Stake In Circassia Pharmaceuticals

Sept 16 (Reuters) - Circassia Pharmaceuticals PLC <CIRCI.L>::WOODFORD INVESTMENT MANAGEMENT DISCLOES LESS THAN 5% STAKE AS OF SEPT. 13 VERSUS PRIOR STAKE OF 19.95% IN CIRCASSIA PHARMACEUTICALS - FILING.

Circassia Pharmaceuticals Appoints Jonathan Emms To Newly-Created COO Role

Aug 12 (Reuters) - Circassia Pharmaceuticals PLC <CIRCI.L>::CIRCASSIA PHARMACEUTICALS PLC - ANNOUNCES APPOINTMENT OF JONATHAN EMMS TO NEWLY-CREATED ROLE OF CHIEF OPERATING OFFICER.CIRCASSIA PHARMACEUTICALS PLC - SENIOR VICE PRESIDENT OF RESEARCH AND DEVELOPMENT ROD HAFNER WILL STEP DOWN FROM BOARD.

Woodford Investment Management Cuts Stake To 19.95% From 24.47% In Circassia Pharmaceuticals

July 8 (Reuters) - Circassia Pharmaceuticals PLC <CIRCI.L>::WOODFORD INVESTMENT MANAGEMENT LTD CUTS STAKE TO 19.95% FROM 24.47% IN CIRCASSIA PHARMACEUTICALS PLC - FILING.

St. James's Place Dissolves Stake In Circassia Pharmaceuticals - Filing

July 2 (Reuters) - Circassia Pharmaceuticals PLC <CIRCI.L>::ST. JAMES'S PLACE PLC GROUP OF COMPANIES DISSOLVES STAKE IN CIRCASSIA PHARMACEUTICALS PLC AS OF JULY 1, FROM 3.8 PERCENT EARLIER - FILING.

St. James's Place PLC Group Of Companies Discloses 3.8% Stake In Circassia Pharmaceuticals As Of June 5 - Filing

June 7 (Reuters) - Circassia Pharmaceuticals PLC <CIRCI.L>::ST. JAMES'S PLACE PLC GROUP OF COMPANIES DISCLOSES 3.8% STAKE IN CIRCASSIA PHARMACEUTICALS AS OF JUNE 5 - FILING.

Woodford Investment Management Discloses 24.47% Stake As Of June 5 Vs Prior Stake Of 28.03% In Circassia Pharmaceuticals - Filing

June 6 (Reuters) - Circassia Pharmaceuticals PLC <CIRCI.L>::WOODFORD INVESTMENT MANAGEMENT DISCLOSES 24.47% STAKE AS OF JUNE 5 VERSUS PRIOR STAKE OF 28.03% IN CIRCASSIA PHARMACEUTICALS - FILING.

Circassia Pharma FY Underlying Cont. Ops Revenue 48.3 Mln Stg Versus 46.3 Mln Stg

May 1 (Reuters) - Circassia Pharmaceuticals PLC <CIRCI.L>::FY UNDERLYING REVENUE FROM CONTINUING. OPERATIONS £48.3M VERSUS £46.3M.UNDERLYING LOSS FOR YEAR £25.9M VERSUS LOSS OF £34.5M.

US FDA Approves Circassia Pharma and AstraZeneca's Duaklir Pressair For Patients With COPD

April 17 (Reuters) - AstraZeneca PLC <AZN.L>::US FOOD AND DRUG ADMINISTRATION APPROVES DUAKLIR® PRESSAIR® (ACLIDINIUM/FORMOTEROL) FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).CIRCASSIA PHARMACEUTICALS PLC - U.S. FDA APPROVES DUAKLIR PRESSAIR FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.CIRCASSIA PHARMACEUTICALS PLC - ONLY TWICE-DAILY LAMA /LABA IN U.S. WITH COPD EXACERBATION DATA INCLUDED IN ITS PRESCRIBING INFORMATION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up